Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III , randomized, open‐label, controlled trial-Reference-Cited by-同舟云学术

Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III , randomized, open‐label, controlled trial

Published:2021-05-27 Issue:8 Volume:23 Page:1786-1794
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Feng Wenhuan¹²^ORCID,Chen Wei¹,Jiang Shan³,Du Liying⁴,Zhu Dalong¹^ORCID

Affiliation:

1. Department of Endocrinology Drum Tower Hospital Affiliated to Nanjing University Medical School Nanjing China

2. Department of Endocrinology, Drum Tower Clinical Hospital Medical School of Southeast University Nanjing China

3. Lilly (Shanghai) Management Co., Ltd Shanghai China

4. Lilly Suzhou Pharmaceutical Co., Ltd Shanghai China

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14392

Reference23 articles.

1. Type 2 Diabetes

2. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

3. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study

4. American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan – 2015

5. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review;BMJ Open Diabetes Research & Care;2024-05

2. A phase-I randomized euglycemic clamp study to demonstrate the pharmacokinetic and pharmacodynamic equivalence of an insulin degludec biosimilar (B01411) with the reference product in healthy Chinese volunteers;Expert Opinion on Investigational Drugs;2023-08-03

3. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial;Nature Medicine;2023-05-25

4. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial;Diabetes Therapy;2022-04-26

5. New Insulins, Biosimilars, and Insulin Therapy;Diabetes Technology & Therapeutics;2022-04-01